The aim of our study is to evaluate the impact of Ialuril® on symptom and bother related to nocturia, in men with bladder pain syndrome (BPS) after radiotherapy for prostate cancer.
MATERIAL & METHODS: Twenty-three consecutive patients (mean age: 67.9) with bladder pain syndrome due to pelvic irradiation for locally advanced prostate cancer (16 treated with radical prostatectomy plus radiotherapy and 7 with radiotherapy alone) were enrolled from Nocturia was assessed by item 3 (Q3) of the Interstitial Cystitis Symptoms Index (ICSI, the "symptom" nocturia) and the item 2 (Q2) of the Interstitial Cystitis Problem Index (ICPI, the "bother" nocturia). Both questionnaires were self-administered immediately after RT and at the end of treatment with Ialuril (12 th weeks) to evaluate the relapse of symptoms.
Data were analyzed with Paired samples T test, and subsequently adjusted for age, baseline ICSI-Q3, baseline ICSI Total score and age, ICPI-Q2, ICPI Total score in two separate logistic regression models.
RESULTS:
